Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment

Cetuximab is an anti-EGFR monoclonal antibody with antitumor efficacy in metastatic colorectal cancer harboring wild-type K-Ras gene. However, not all patients K-Ras wild-type benefit from Cetuximab, underscoring the need for additional markers to help in patient selection. Preclinical evidence sugg...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pantano, Francesco, Guida, Francesco Maria, Vivaldi, Caterina, Vincenzi, Bruno, Grande, Enrique, Garrote, Mercedes Rodriguez, Caraglia, Michele, Silvestris, Nicola, Vasile, Enrico, Masi, Gianluca, Falcone, Alfredo, Tonini, Giuseppe, Santini, Daniele
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2013
Assuntos:
Letter to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3813561/
https://ncbi.nlm.nih.gov/pubmed/23760487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24346
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados